STAAR Surgical Company (NASDAQ:STAA) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of STAAR Surgical Company (NASDAQ:STAA) have been given a consensus recommendation of “Reduce” by the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and ten have assigned a hold recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $20.6667.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus set a $28.00 price target on shares of STAAR Surgical and gave the company a “hold” rating in a research report on Thursday, August 7th. Mizuho lifted their price target on shares of STAAR Surgical from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Canaccord Genuity Group lifted their price target on shares of STAAR Surgical from $20.00 to $28.00 and gave the company a “hold” rating in a research report on Wednesday, August 6th. Piper Sandler raised shares of STAAR Surgical to a “hold” rating in a research report on Wednesday, June 18th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of STAAR Surgical in a research report on Saturday, September 27th.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors and hedge funds have recently bought and sold shares of STAA. GAMMA Investing LLC increased its position in STAAR Surgical by 4,086.0% during the first quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $258,000 after acquiring an additional 14,301 shares during the period. SG Americas Securities LLC increased its position in STAAR Surgical by 123.1% during the first quarter. SG Americas Securities LLC now owns 49,072 shares of the medical instruments supplier’s stock worth $865,000 after acquiring an additional 27,075 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in STAAR Surgical by 75.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 21,234 shares of the medical instruments supplier’s stock worth $374,000 after acquiring an additional 9,125 shares during the period. Exchange Traded Concepts LLC increased its position in STAAR Surgical by 25.3% during the first quarter. Exchange Traded Concepts LLC now owns 45,568 shares of the medical instruments supplier’s stock worth $803,000 after acquiring an additional 9,194 shares during the period. Finally, ORG Partners LLC bought a new position in STAAR Surgical during the first quarter worth $294,000. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Down 0.4%

NASDAQ STAA opened at $26.72 on Wednesday. The stock has a market capitalization of $1.32 billion, a PE ratio of -13.84 and a beta of 0.82. The company has a 50 day moving average price of $26.66 and a two-hundred day moving average price of $20.75. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $33.78.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.